- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: PF 3893787 | PF-03893787 | ZPL-389 | ZPL-3893787 | ZPL389 | ZPL3893787
Compound class: Synthetic organic
Comment: Adriforant (ZPL-3893787) was a clinical stage immunomodulatory compound being developed by Ziarco Pharma (a Novartis subsidiary). Mechanistically it is a selective histamine H4 receptor antagonist. Novartis announced in their second-quarter financial report of 2020, that they were terminating the adriforant development programme.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Ehling S, Roßbach K, Dunston SM, Stark H, Bäumer W. (2016)
Allergic inflammation is augmented via histamine H4 receptor activation: The role of natural killer cells in vitro and in vivo.
J Dermatol Sci, 83 (2): 106-15. [PMID:27155791]
2. Panula P, Chazot PL, Cowart M, Gutzmer R, Leurs R, Liu WL, Stark H, Thurmond RL, Haas HL. (2015)
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.
Pharmacol Rev, 67 (3): 601-55. [PMID:26084539]
3. Werfel T, Layton G, Yeadon M, Whitlock L, Osterloh I, Jimenez P, Liu W, Lynch V, Asher A, Tsianakas A et al.. (2019)
Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis.
J Allergy Clin Immunol, 143 (5): 1830-1837.e4. [PMID:30414855]